Benzinga's Top Pre-Market NASDAQ Losers (SVNT, CRXL, XLNX, RIMM)

Savient Pharmaceuticals Inc

dipped 2.87% to $20.00 in the pre-market session. SVNT drug, Krystexxa, was approved by the Food and Drug Administration. Crucell NV

lost 0.53% to $31.85 in the pre-market session.CRXL had announced its acquisition by Johnson & Johnson

. Xilinx Inc

slipped 0.08% to $26.43 in the pre-market trading. XLNX demonstrated, at Intel Developer Forum, Intel QuickPath Technology for FPGAs. Research In Motion Limited

fell 0.06% to $46.69 in the pre-market session.RIMM had reported strong Q2 earnings. Read more